Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03738943 · ClinicalTrials.gov registry record · Early Phase 1
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults
A Early Phase 1 study, sponsored by Colorado State University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT03738943 is a Early Phase 1 study that has completed, run by Colorado State University. The registered enrollment target is 9 participants.
The verdict
NCT03738943, a Early Phase 1 study, has completed, sponsored by Colorado State University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Previous research has identified adenosine triphosphate (ATP) as an important vasodilator that is released from red blood cells during exercise and exposure to hypoxic environments in adult humans. Further, older adults appear to have lower blood flow during both of these stressors and also have lower amounts of ATP released from their red blood cells. However, the contribution of ATP to vasodilation in response to exercise and hypoxia is currently unknown due to the lack of an effective ATP receptor antagonist. We aim to determine whether Vitamin B6 or its metabolite, Pyridoxal-5-Phosphate (PLP) is an effective ATP receptor antagonist.
Interventions
- DRUG Acetylcholine
- DRUG Sodium Nitroprusside
- DRUG Adenosine Triphosphate
- DRUG Adenosine Diphosphate
- DRUG Adenosine Monophosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2021-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03738943
The ClinicalTrials.gov registry entry for NCT03738943 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Colorado State University, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Acetylcholine is the first listed.
NCT03738943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03738943 about?
NCT03738943 is a clinical study titled "Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults". Previous research has identified adenosine triphosphate (ATP) as an important vasodilator that is released from red blood cells during exercise and exposure to hypoxic environments in adult humans. Further, older adults appear to have lower blood flow during both of these stressors and also have low...
What is the current status of trial NCT03738943?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2019-02-07. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT03738943?
The interventions under investigation include: Acetylcholine (DRUG), Sodium Nitroprusside (DRUG), Adenosine Triphosphate (DRUG), Adenosine Diphosphate (DRUG), Adenosine Monophosphate (DRUG).
Who is sponsoring clinical trial NCT03738943?
This trial is sponsored by Colorado State University, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.